We may earn if you use our links. details
FORECASTEDNationwide

Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies for cancer research or clinical care. This NOFO solicits R33 applicatio

Plain-language brief

What this opportunity funds

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies for cancer research or clinical care. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development, enhancements, optimizations, and rigorous technical validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, and/or epidemiology. Projects that are in-scope include technologies with new or significantly improved technical capabilities to measure, analyze, model, or interrogate cancer-related systems. These may include, but are not limited to, advanced molecular and cellular analysis platforms, multi-omic and spatial profiling methods, imaging and sensing technologies, immuno-engineering approaches, and innovations in biospecimen processing, modeling, and quality assessment. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer applications. Projects proposing application of existing technologies where the novelty resides in the clinical target or biological question being pursued are not appropriate for this solicitation. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Eligibility at a glance

Eligible applicants
Private institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Native American tribal governments (Federally recognized), City or township governments, County governments, For profit organizations other than small businesses, State governments, Public housing authorities/Indian housing authorities, Others (see text field entitled "Additional Information on Eligibility" for clarification), Public and State controlled institutions of higher education, Independent school districts, Native American tribal organizations (other than Federally recognized tribal governments), Special district governments, Small businesses, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Eligible locations
Eligible applicants across the United States
Eligible activities
Health
Matching requirement
Not specified
Registration
SAM.gov, Grants.gov

Application process

  1. Read the complete official notice and confirm every eligibility rule.
  2. Complete required registrations early; federal registrations can take time.
  3. Build the budget, work plan, evidence, and attachments requested by the sponsor.
  4. Submit through the official portal and retain the confirmation.

Change history

No material changes have been recorded since this opportunity entered the hub.

Related opportunities

FORECASTEDNationwide

Translational Research in Maternal and Pediatric Pharmacology and Therapeutics

National Institutes of Health

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), as part of its stewardship of Congressionally-mandated activities under the Best Pharmaceuticals for Children Act (BPCA) and implementation of recommendations of the Task Force on Research Specific to Pregna

Award
Amount not specified
Deadline
Not specified
Intermediary grantFor profit organizations other than small businessesIntermediary / support
source verifiedVerified Aug 21, 2026
FORECASTEDNationwide

Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)

National Institutes of Health

Type 1 diabetes (T1D) is a complex disease involving interactions among many different cell types, tissues, organs and biological processes. Genetics, the environment, and lifestyle all play a role in disease development and progression. Over the past two decades, the National Institute of Diabetes

Award
Amount not specified
Deadline
Not specified
Intermediary grantIndependent school districtsIntermediary / support
source verifiedVerified Aug 21, 2026
FORECASTEDNationwide

Partnership with Common Fund Data Ecosystem Resources

National Institutes of Health

The NIH Office of Strategic Coordination (Common Fund) has generated many valuable and widely available datasets. The Common Fund Data Ecosystem is helping to ensure that all Common Fund (CF) data are Findable, Accessible, Interoperable, and Reusable (FAIR). The purpose of this Notice of Funding Opp

Award
Up to $1,200,000
Deadline
Not specified
Intermediary grantCity or township governmentsIntermediary / support
source verifiedVerified Aug 7, 2026